Shots:
- The 2 studies evaluated IPDE therapy for lower urinary tract symptoms (LUTS) secondary to BPH, assessing delivery of paclitaxel-eluting bioabsorbable implants through transperineal & transrectal approaches
- In the transperineal study (n=20), IPDE improved IPSS by 15 points & Qmax by ~4 mL/s at 1yr., achieving benefit in 80% pts, while the transrectal study (n=11) showed IPSS improved by 15 points as early as 1mos. & sustained through ≥6mos., plus 4.1mL/s Qmax increase, & 23% prostate volume reduction at 6mos.
- The IPDE platform enables single administration localized drug delivery to the enlarged prostate, with Resurge planning larger global PBO-controlled studies, while engaging regulators & stakeholders to support further development
Ref: PRnewswire | Image: Resurge Therapeutics | Press Release
Related News: Revvity Receives FDA Clearance for Total Testosterone ChLIA Assay
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
